Adagio Medical obtains CE Mark for VT catheter, closes business combination with $35M pro forma cash

Adagio Medical Holdings, Inc.

CE Mark approval and commercial launch of vCLAS catheter for ventricular tachycardia in select European markets.
FDA approved FULCRUM-VT pivotal IDE study for VT cryoablation system; patient enrollment starts September 2024.
Closed business combination with ARYA Sciences Acquisition Corp; shares listed on Nasdaq under ADGM on Aug 1, 2024.
Raised approx. $84.2M from trust, PIPE, and convertible financing; pro forma cash ~$35M after transaction costs.

This headline and bullets were generated automatically by deepseek-v4-flash:cloud@v2 from the public filing. Read the source on SEC.gov before relying on any specific claim. Not investment advice. See methodology for how this pipeline works.